Published in Mol Ther on August 21, 2014
In vivo secretion of anti-CD3 × anti-tumor bispecific antibodies by gene-modified cells: over a decade of T-cell engagement. Mol Ther (2015) 0.85
The Evolution of T-cell Therapies for Solid Malignancies. Clin Cancer Res (2015) 0.84
T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies. Sci Rep (2016) 0.82
Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice. Blood Cancer J (2016) 0.79
CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia. Mol Ther (2016) 0.78
Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors. Oncoimmunology (2016) 0.78
Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells. Oncotarget (2016) 0.75
Balanced secretion of anti-CEA x anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity. Gene Ther (2017) 0.75
Response to "in vivo secretion of anti-CD3 × anti-tumor bispecific antibodies by gene-modified cells: over a decade of T-cell engagement". Mol Ther (2015) 0.75
T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC. Mol Ther Oncolytics (2017) 0.75
In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy. Mol Ther Methods Clin Dev (2017) 0.75
CD28 and 41BB costimulation enhances the effector function of CD19-specific engager T cells. Cancer Immunol Res (2017) 0.75
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med (2006) 15.04
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 10.63
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 7.99
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med (2008) 7.80
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A (2009) 5.36
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science (2008) 5.30
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood (2009) 4.98
Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood (2008) 3.85
The basic principles of chimeric antigen receptor design. Cancer Discov (2013) 3.28
Improving T cell therapy for cancer. Annu Rev Immunol (2007) 3.10
T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med (2007) 3.07
Immune resistance orchestrated by the tumor microenvironment. Immunol Rev (2006) 2.83
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood (2009) 2.79
Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res (2009) 2.58
Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia (2006) 2.35
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia (2010) 2.22
The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res (2008) 2.21
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther (2002) 1.96
T-cell therapy at the threshold. Nat Biotechnol (2012) 1.91
Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood (2002) 1.89
Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J (2014) 1.64
Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. Mol Immunol (1998) 1.56
Blinatumomab: a historical perspective. Pharmacol Ther (2012) 1.52
Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer J (2010) 1.52
Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol (2013) 1.39
Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother (2010) 1.38
Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther (2011) 1.36
Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer. J Immunol (2008) 1.32
T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther (2012) 1.21
Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther (2013) 1.20
T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther (2013) 1.07
Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res (2012) 1.06
Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on. Cancer Immun (2012) 0.98
Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Mol Ther (2013) 0.95
EphA2-dependent molecular targeting therapy for malignant tumors. Curr Cancer Drug Targets (2011) 0.94
Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future. BioDrugs (2013) 0.90
The intriguing options of multispecific antibody formats for treatment of cancer. Cancer Genomics Proteomics (2013) 0.85
Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties. Mol Immunol (2007) 0.81